Annual report pursuant to Section 13 and 15(d)

Non-controlling Interest (Details Textual)

v3.10.0.1
Non-controlling Interest (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Sep. 05, 2018
Aug. 31, 2015
Aug. 29, 2015
Dec. 31, 2018
Dec. 31, 2017
Noncontrolling Interest [Line Items]          
Equity Method Investment, Ownership Percentage       83.00%  
Net Loss Attributable to Non-controlling Interest       $ (54,000) $ (318,000)
Stockholders' Equity Attributable to Noncontrolling Interest       (2,909,000) (1,914,000)
Related Party Transaction, Expenses from Transactions with Related Party $ 321,000        
Research and Development Expense 102,000     $ 11,844,000 18,784,000
Fair Value Of Shares Issued $ 285,000        
Synthetic Biomics Inc [Member]          
Noncontrolling Interest [Line Items]          
Additional Number Of Common Stock To Be Issued 2,420,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners (17.00%)        
SYN Biomics [Member]          
Noncontrolling Interest [Line Items]          
Equity Method Investment, Ownership Percentage 88.50%     83.00%  
Net Loss Attributable to Non-controlling Interest       $ 2,900,000 1,900,000
Noncontrolling Interest, Ownership Percentage by Parent 11.50%   8.50% 17.00%  
Consolidation, Eliminations [Member]          
Noncontrolling Interest [Line Items]          
Net Loss Attributable to Non-controlling Interest         54,000
Dr. Pimentels [Member]          
Noncontrolling Interest [Line Items]          
Net Loss Attributable to Non-controlling Interest         1,600,000
Dr. Pimentels [Member] | Consolidation, Eliminations [Member]          
Noncontrolling Interest [Line Items]          
Stockholders' Equity Attributable to Noncontrolling Interest         $ 505,000
Cedars-Sinai Medical Center [Member]          
Noncontrolling Interest [Line Items]          
Number Of Common Stock To Be Issued 50,000        
Cedars-Sinai Medical Center [Member] | Synthetic Biomics Inc [Member]          
Noncontrolling Interest [Line Items]          
Additional Number Of Common Stock To Be Issued 2,420,000        
Number Of Common Stock To Be Held By Related Party 7,480,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners (17.00%)        
Stock Purchase Agreement [Member]          
Noncontrolling Interest [Line Items]          
Conversion of Stock, Shares Issued   38,572 38,572    
Research and Development Expense $ 36,000,000